Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been ...

Novo Nordisk's anti-TFPI antibody concizumab has ... Concizumab – which has the trade name Alhemo – is already approved in other markets, including Japan, Australia, and Switzerland, but ...

Novo Nordisk has beaten Wall Street's revenue estimates ... while its competitor has only one [Alhemo]. Eli Lilly's R&D portfolio includes 77 projects, 22 of which are in Phase 3.

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.

Qfitlia’s monthly regimen already gives it an advantage over Novo Nordisk’s daily Alhemo (concizumab) and Pfizer’s weekly Hympavzi (marstacimab), two of the most recent drugs approved by the ...

However, concizumab has been approved in Canada as Alhemo, but requires once-daily subcutaneous dosing that has some market observers questioning its commercial viability. Novo Nordisk insists it ...

Since the study was conducted, however, two new agents have gained approval. In December 2024, the FDA approved Novo Nordisk's Alhemo (concizumab) to prevent or reduce frequent bleeding episodes for ...

Key Features of Qfitlia ? Bimonthly Subcutaneous Therapy – Compared to Pfizer’s (NYSE:PFE) Hympavzi (weekly injection) and Novo Nordisk’s (NYSE:NVO) Alhemo (daily injection), Qfitlia reduces treatment ...